Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xerxes Pundole

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 12, 2024
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world studyHossein Borghaei, Xerxes Pundole, Laura Sangaré, et al.
Arthritis Care & Research|August 18, 2020
Cervical Cancer Screening in Women With Systemic Lupus ErythematosusSebastian Bruera, Xiudong Lei, Richard Zogala, et al.
Lung Cancer (Amsterdam, Netherlands)|June 2, 2026
Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysisJessie Wang, Rumbidzai Takundwa, Hongbo Yang, et al.
Targeted Oncology|November 6, 2023
Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung CancerLauren C Bylsma, Xerxes Pundole, Chia-Hsin Ju, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2024
A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune diseaseMaria A Lopez-Olivo, Johncy J Kachira, Noha Abdel-Wahab, et al.
International Journal of Cancer|March 13, 2026
Treatment patterns and clinical outcomes in real-world patients with small-cell lung cancer in South Korea: A single-center experienceSehhoon Park, Danbee Kang, Jin Lee, et al.
Archives of Osteoporosis|April 6, 2018
Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantationXerxes Pundole, William A Murphy, Chidinma C Ebede, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 29, 2020
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitorsMaria E Suarez-Almazor, Xerxes Pundole, Noha Abdel-Wahab, et al.
Clinical Epidemiology|December 26, 2025
A Multi-Country Study of the Clinical Course of Extensive-Stage Small Cell Lung Cancer: A Six-Study Analysis of Real-World Treatment Patterns and OutcomesXerxes Pundole, Diana Younan, Cathy W Critchlow, et al.
Clinical and Experimental Rheumatology|August 30, 2019
Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)Manuel Ramos-Casals, Alexandre Maria, María E Suárez-Almazor, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Lung Cancer (Amsterdam, Netherlands)|June 12, 2024
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world studyHossein Borghaei, Xerxes Pundole, Laura Sangaré, et al.
Arthritis Care & Research|August 18, 2020
Cervical Cancer Screening in Women With Systemic Lupus ErythematosusSebastian Bruera, Xiudong Lei, Richard Zogala, et al.
Lung Cancer (Amsterdam, Netherlands)|June 2, 2026
Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysisJessie Wang, Rumbidzai Takundwa, Hongbo Yang, et al.
Targeted Oncology|November 6, 2023
Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung CancerLauren C Bylsma, Xerxes Pundole, Chia-Hsin Ju, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2024
A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune diseaseMaria A Lopez-Olivo, Johncy J Kachira, Noha Abdel-Wahab, et al.
International Journal of Cancer|March 13, 2026
Treatment patterns and clinical outcomes in real-world patients with small-cell lung cancer in South Korea: A single-center experienceSehhoon Park, Danbee Kang, Jin Lee, et al.
Archives of Osteoporosis|April 6, 2018
Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantationXerxes Pundole, William A Murphy, Chidinma C Ebede, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 29, 2020
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitorsMaria E Suarez-Almazor, Xerxes Pundole, Noha Abdel-Wahab, et al.
Clinical Epidemiology|December 26, 2025
A Multi-Country Study of the Clinical Course of Extensive-Stage Small Cell Lung Cancer: A Six-Study Analysis of Real-World Treatment Patterns and OutcomesXerxes Pundole, Diana Younan, Cathy W Critchlow, et al.
Clinical and Experimental Rheumatology|August 30, 2019
Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)Manuel Ramos-Casals, Alexandre Maria, María E Suárez-Almazor, et al.
Pageof 4